Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06977711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 29, 2026 (before its estimated October 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 44 words
  2. Primary completion date: Apr 15, 2026 to Oct 15, 2026
    • Study completion date: Jul 31, 2026 to Apr 1, 2027
    v4
  3. Start date changed from estimate of Jun 4, 2025 to Jun 20, 2025v3
  4. Start date: May 20, 2025 to Jun 4, 2025
    • Eligibility criteria expanded, about 16 words
    • Site contacts updated at 1 of 2 sites
    • Study title expanded, about 3 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: 1. To assess the safety and how well the participants tolerate the treatment 2. Assess the response of the tumor to treatment to estimate complete response 3. Assess the response of the tumor to treatment to estimate progression-free survival
Trial Details
NCT Number NCT06977711
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions
(from sponsor)		 Diffuse Large B-cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov